Immunology and Microbiology
Primary Immunodeficiency
100%
Common Variable Immunodeficiency
97%
COVID-19
95%
T Cell
82%
Severe Acute Respiratory Syndrome Coronavirus 2
75%
Immunodeficiency
65%
Immunogenicity
59%
B Cell
45%
Immune Response
43%
Prevalence
37%
Immune Dysregulation
36%
Immunity
29%
Lymphocyte Proliferation
26%
Binding Antibody
24%
Intravenous Immunoglobulin
24%
Omicron Coronavirus Variant
23%
Neutralizing Antibody
20%
Autoinflammatory Syndromes
19%
Inflammatory Bowel Disease
19%
STAT3
19%
Norovirus
19%
Immunoglobulin
18%
Hypogammaglobulinemia
18%
Granuloma
18%
Prednisolone
16%
Autoimmunity
16%
CD4
15%
Booster Dose
15%
Sarcoidosis
14%
Neutrophil
13%
Humoral Immune Deficiency
13%
Spike
13%
Lineages
13%
Germ Cell
13%
T-Helper Cell
12%
Autoimmune Disease
12%
Immunocompetent Cell
12%
Macrophage
12%
Biological Product
11%
Next Generation Sequencing
11%
Cytotoxic T-Cell
11%
Immunosuppressive Drug
11%
Proteomics
10%
Immunology
9%
Graves' Ophthalmopathy
9%
Postcovid Syndrome
9%
Human Immunodeficiency Virus
9%
Lupus Anticoagulant
9%
Thymosin
9%
CD8
9%
Medicine and Dentistry
COVID-19
41%
Immune Deficiency
40%
Systematic Review
39%
Immunoglobulin A
39%
Leniolisib
29%
Lymphocyte Proliferation
28%
Phosphoinositide 3-Kinase
27%
Primary Immunodeficiency
26%
Diseases
25%
Severe Acute Respiratory Syndrome Coronavirus 2
25%
Immunoglobulin
24%
Infection
22%
Autoimmunity
22%
middle age
22%
Interstitial Lung Disease
19%
Omicron Coronavirus Variant
19%
Immunogenicity
19%
Netherton Syndrome
19%
Inflammatory Bowel Disease
19%
Sarcoidosis
19%
Meta-Analysis
19%
Messenger RNA
18%
Immunoglobulin M
18%
Immunity
16%
Immunodeficiency
16%
Diagnosis
15%
Cohort Analysis
14%
Autoinflammatory Disease
14%
Placebo
14%
Prevalence
14%
Lymphadenopathy
14%
Autoimmune Disease
12%
In Vitro
12%
Adverse Event
12%
Frailty
11%
Splenomegaly
11%
Immunocompromised Patient
11%
Immune Dysregulation
10%
COVID-19 Vaccine
10%
Population
10%
Health Care
9%
Hypogammaglobulinemia
9%
Observational Study
9%
Human Immunodeficiency Virus
9%
Granulomatosis
9%
Psoriasis
9%
Cardiovascular Disease
9%
Rheumatoid Arthritis
9%
microRNA
9%
Cardiovascular Mortality
9%
Pharmacology, Toxicology and Pharmaceutical Science
Infection
31%
Syndrome
31%
Immune Deficiency
30%
Immunogenicity
29%
Leniolisib
29%
Common Variable Immunodeficiency
29%
Messenger RNA
27%
Phosphatidylinositol 3 Kinase
27%
SARS Coronavirus
24%
Prevalence
23%
Biological Marker
22%
Immunoglobulin A
19%
Netherton Disease
19%
Interstitial Lung Disease
19%
Granulomatosis
19%
Diseases
15%
Adverse Event
14%
Placebo
14%
Hospital Mortality
13%
Immunoglobulin M
12%
Prednisolone
12%
Immunoglobulin
12%
Randomized Controlled Trial
11%
Autoimmune Disease
11%
COVID-19 Vaccine
10%
Interferon Induced Helicase C Domain Containing Protein 1
9%
Antiphospholipid Antibody
9%
Autoinflammatory Disease
9%
Atherosclerosis
9%
Clinical Feature
9%
Dupilumab
9%
HIV
9%
Cardiovascular Mortality
9%
Systemic Treatment
9%
Synapsin I
9%
Prospective Cohort Study
9%
Dermatomyositis
9%
STAT Protein
9%
Frailty
9%
Lupus Anticoagulant
9%
Liposome
9%
Inflammatory Bowel Disease
9%
Anakinra
9%
Ixekizumab
9%
Endocrine Ophthalmopathy
9%
Cardiovascular Disease
9%
C Reactive Protein
8%
Antiviral Drug
7%
Organ Dysfunction Score
7%
Lymphadenopathy
7%
